Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of carbonyl reductase and its mutants in the synthesis of indacaterol pharmaceutical intermediates

A reductase and mutant technology, which is applied in the field of bioengineering, can solve the problems of large substrate II hindrance and no conversion activity of carbonyl reductase, and achieve the effects of improved conversion activity, simple and convenient preparation method, and environmental friendliness

Active Publication Date: 2022-01-25
TIANJIN INST OF IND BIOTECH CHINESE ACADEMY OF SCI
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] In the currently known reports, there is no report on the biocatalytic preparation of chiral alcohols using substrate II or its analogues. The main reason is that substrate II has a large steric hindrance, and most carbonyl reductases do not convert it. Vitality, and as an intermediate of the drug indacaterol, the configuration of the product should be the R configuration, and the optical purity should be >99%

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of carbonyl reductase and its mutants in the synthesis of indacaterol pharmaceutical intermediates
  • Application of carbonyl reductase and its mutants in the synthesis of indacaterol pharmaceutical intermediates
  • Application of carbonyl reductase and its mutants in the synthesis of indacaterol pharmaceutical intermediates

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0018] Embodiment 1: RasADH and mutant gene obtained

[0019] 1.1 Synthesis of RasADH gene and acquisition of its mutant gene

[0020] The RasADH gene is derived from Ralstonia sp.DSM 6428, and has a crystal structure (PDB: 4BMS). According to the codon preference of Escherichia coli, the gene is optimized and sent to the company for synthesis. The codon-optimized genes are respectively A NdeI (CATATG) restriction site was added at the 5' end, and an XhoI (CTCGAG) restriction site was added at the 3' end, and cloned into the PET21a vector. Since the crystal structure of RasADH is known, Discovery Studio 4.1 software was used to dock the substrate II with its three-dimensional structure to obtain the interaction relationship between the substrate and the protein. According to the docking results, the amino acids 189, 191, 202, and 205 near the active center were selected for site-directed mutagenesis, and the PET21a plasmid with the RasADH gene was used as a template and prime...

Embodiment 2

[0034] Embodiment 2: the construction of RasADH and its mutant expression bacteria

[0035] After the digested and purified PCR product was transformed into Escherichia coli BL21(DE3) competent cells by chemical transformation, single clones were picked and placed in 4 mL of LB medium containing ampicillin (10 mg / mL), and fresh bacterial liquid was taken Sent to a sequencing company for sequencing, and the sequencing results showed that the correct mutant was the strain expressing the RasADH mutant.

Embodiment 3

[0036] Example 3: Induced expression of RasADH and mutants thereof

[0037] Prepare 50 mL of seed liquid, and the medium is LB liquid medium (peptone 10 g / L, yeast powder 5 g / L, NaCl 10 g / L), pick a single colony of genetically engineered bacteria with an inoculation loop and insert it into the medium, at 37 °C, Incubate overnight at 200 rpm. The seed solution cultivated overnight was transferred to the fermentation medium with an inoculum size of 1%, and cultivated at 25°C and 200rpm for 20h. After 5 mL of the fermentation broth was concentrated and ultrasonicated, the activity of RasADH and its mutants was detected. Enzyme activity definition of RasADH and its mutants: the amount of enzyme needed to consume 1 μmol NADPH per minute is 1 enzyme activity unit (U).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a carbonyl reductase (RasADH) derived from Ralstonia sp. DSM 6428 and its mutant as a biocatalyst to catalyze 5-(α-haloacetyl)-8-substituted oxy-(1H)- Quinolin-2-one synthesis of indacaterol chiral intermediate. RasADH has low enzymatic activity when reducing the above substrates, and a large amount of bacteria or protein needs to be added during transformation. By means of protein engineering, the present invention has obtained seven mutants, RasADH E189A, RasADH Q191A, RasADH R202F, RasADH F205A, RasADH Q191A / F205A, RasADH Q191A / R202F / F205A, RasADH E189A / Q191A / R202F / F205A on the above substrates The enzymatic activity of the product has been significantly improved, and when converting substrates, it can be converted efficiently, the product configuration is R, and the stereoselectivity is >99%.

Description

technical field [0001] The invention belongs to the technical field of bioengineering, and specifically relates to carbonyl reductase RasADH and mutants from Ralstonia sp.DSM 6428, sequences encoding the enzyme, and asymmetric reduction of carbonyl reductases and mutants in indacaterol pharmaceutical intermediates, Application in the preparation of highly optically pure chiral alcohols. Background technique [0002] Indacaterol is a β-selective adrenoceptor agonist with potent bronchodilatory activity and is useful in the treatment of asthma and chronic obstructive pulmonary disease (COPD). Since 2009, it has been listed in more than 70 countries and regions around the world. In June 2012, it was approved by the State Food and Drug Administration for listing in China. It is the first long-acting β2 receptor agonist approved for the treatment of COPD in China (Seth, H.D.; Sultan, S.; Gotfried, M.H. Role of Indacaterol, a Once-Daily Bronchodilator, in Chronic Obstructive Pulm...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C12N9/04C12P17/12
CPCC12N9/0006C12Y101/01184C12P17/12
Inventor 张红榴陈曦李娟冯进辉吴洽庆朱敦明
Owner TIANJIN INST OF IND BIOTECH CHINESE ACADEMY OF SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com